Bone Marrow Transplantation

Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.  57:1597-1599. 2022

Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients.  57:1079-1085. 2022

Genome-wide variants and polygenic risk scores for cognitive impairment following blood or marrow transplantation.  57:925-933. 2022

A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.  57:295-298. 2022

Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.  57:309-311. 2022

Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation 2022

Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.  56:1364-1372. 2021

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.  55:1810-1816. 2020

Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian center.  55:1181-1183. 2020

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.  54:1245-1253. 2019

LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.  54:625-628. 2019

Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.  53:1345-1348. 2018

Clinical-scale manufacturing of γδ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis.  53:766-769. 2018

Frailty: The missing piece of the pre-hematopoietic cell transplantation assessment?.  53:3-10. 2018

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysis.  52:1616-1622. 2017

Immune-mediated cytopenia in pediatric primary immune deficiency patients following HSCT.  52:1571-1574. 2017

Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: Past, present and future.  52:1241-1248. 2017

Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: Analysis of oxidative stress in lung fibroblasts.  52:765-768. 2017

Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure.  52:157-158. 2017

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.  50:1513-1518. 2015

A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.  50:1416-1423. 2015

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.  50:197-203. 2015

Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT.  50:142-144. 2015

Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.  49:1239-1240. 2014

Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: Meta-analysis of trials with biological assignment.  48:562-567. 2013

A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT.  48:461-462. 2013

Growth factor plus preemptive (just-in-time) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.  47:1403-1408. 2012

Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): A report from the BMT Survivor Study.  47:283-290. 2012

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.  46:523-528. 2011

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.  46:64-69. 2011

Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantation.  45:772-773. 2010

Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial).  45:587-589. 2010

Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancy.  42:497-498. 2008

B-cell enrichment and infusion in CD4+/CD8+ T-cell depleted products for donor innate immune lymphocyte infusion: Is risk of EBV-associated lymphocyte post transplantation lymphoproliferative disease a concern?.  41:995-996. 2008

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.  41:715-720. 2008

Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.  40:843-850. 2007

Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation.  39:751-757. 2007

Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: Determination of the best diagnostic approach.  38:371-376. 2006

Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: Report from the bone marrow transplant survivor study.  37:1023-1029. 2006

Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: Single-center experience of 201 patients.  33:389-396. 2004

Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program.  30:741-748. 2002

Pneumonia and sepsis due to fluoroquinolone-resistant Capnocytophaga gingivalis after autologous stem cell transplantation.  28:1171-1173. 2001

Human γδ⁺ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response.  27:601-606. 2001

Validation of self-reported complications by bone marrow transplantation survivors.  25:1191-1196. 2000

Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors.  21:461-471. 1998

Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies.  22:87-90. 1998

Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant.  22:111-113. 1998

Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: Good news and bad news.  19:1157-1161. 1997

De nova chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant.  19:813-817. 1997

Infection and replication of human cytomegalovirus in bone marrow stromal cells: Effects on the production of IL-6, MIP-1α, and TGF-β1.  19:471-480. 1997

Corrigendum: De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant (Bone Marrow Transplantation (1997) 19 (813-817)).  20:523. 1997

In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34⁺ cells.  18:997-1008. 1996

Malignancy-associated pulmonary veno-occlusive disease: Report of a case following autologous bone marrow transplantation and review.  18:755-760. 1996

Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: Clinical and immunologic characteristics.  17:1021-1027. 1996

Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML.  17. 1996

Neurologic complications following bone marrow transplantation for sickle cell disease.  17:405-407. 1996

Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.  16:353-358. 1995

Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.  15:979-981. 1995

Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation.  12:541-546. 1993

Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia.  8:143-145. 1991